GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Medlive Technology Co Ltd (HKSE:02192) » Definitions » Cash Conversion Cycle

Medlive Technology Co (HKSE:02192) Cash Conversion Cycle : 59.15 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Medlive Technology Co Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Medlive Technology Co's Days Sales Outstanding for the six months ended in Dec. 2023 was 77.07.
Medlive Technology Co's Days Inventory for the six months ended in Dec. 2023 was 0.3.
Medlive Technology Co's Days Payable for the six months ended in Dec. 2023 was 18.22.
Therefore, Medlive Technology Co's Cash Conversion Cycle (CCC) for the six months ended in Dec. 2023 was 59.15.


Medlive Technology Co Cash Conversion Cycle Historical Data

The historical data trend for Medlive Technology Co's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlive Technology Co Cash Conversion Cycle Chart

Medlive Technology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial 72.25 37.07 48.91 87.19 72.09

Medlive Technology Co Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.61 81.14 75.01 91.15 59.15

Competitive Comparison of Medlive Technology Co's Cash Conversion Cycle

For the Medical Distribution subindustry, Medlive Technology Co's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medlive Technology Co's Cash Conversion Cycle Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Medlive Technology Co's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Medlive Technology Co's Cash Conversion Cycle falls into.



Medlive Technology Co Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Medlive Technology Co's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=91.67+0.34-19.92
=72.09

Medlive Technology Co's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=77.07+0.3-18.22
=59.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medlive Technology Co  (HKSE:02192) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Medlive Technology Co Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Medlive Technology Co's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Medlive Technology Co (HKSE:02192) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Baijialou Chaoyang North Road, E1 Red Manor International Bonded Innovation Park, Chaoyang District, Beijing, CHN
Medlive is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms to specifically target physicians through different promotional channels. The company uses in-house and third-party content teams to produce advertising for its clients by profiling the user preferences of the physicians on the platform who drive procurement and prescription decisions. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and SaaS solution that help with medical conferences and clinical research. M3, Japan's leading digital healthcare marketing company owns 38.8% of Medlive through a joint venture.
Executives
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
M3, Inc. 2101 Beneficial owner
Sony Group Corporation 2201 Interest of corporation controlled by you
Tian Liping
Zhang Xiaofeng 2101 Beneficial owner
Liu Lingdi 2101 Beneficial owner
Tian Lixin 2101 Beneficial owner
Brown Brothers Harriman & Co. 2502 Approved lending agent
Fidelity Funds 2101 Beneficial owner
Tiantian Co., Limited

Medlive Technology Co (HKSE:02192) Headlines

No Headlines